Denali Therapeutics Inc.
DNLI
$19.00
$1.166.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.67% | -14.15% | -230.75% | -191.12% | -243.56% |
| Total Depreciation and Amortization | -32.76% | -51.09% | -75.77% | -93.47% | -54.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 103.13% | 93.82% | 75.82% | -5.60% | -36.04% |
| Change in Net Operating Assets | -53.50% | 287.60% | 103.30% | 105.84% | 104.14% |
| Cash from Operations | -9.69% | 10.55% | 11.45% | 2.88% | -9.23% |
| Capital Expenditure | -0.11% | -63.11% | -53.13% | -22.98% | 16.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 340.07% | 372.03% | 506.65% | -127.78% | -372.14% |
| Cash from Investing | 316.44% | 344.96% | 444.70% | -135.60% | -485.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 31.40% | -- | -- | -- | -- |
| Issuance of Common Stock | -98.19% | -97.23% | -96.72% | 2,801.92% | 65.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | 100.00% | -- | -- |
| Cash from Financing | -101.44% | -104.84% | -103.82% | 2,617.76% | 57.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.24% | 218.79% | 71.99% | 152.67% | -294.68% |